Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABBV-066 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Stage 1 (low dose SC) | EXPERIMENTAL | Low dose administered by subcutaneous (SC) injection |
| Stage 1 (medium dose SC) | EXPERIMENTAL | Medium dose administered by subcutaneous (SC) injection |
| Stage 1 (high dose SC) | EXPERIMENTAL | High dose administered by subcutaneous (SC) injection |
| Stage 2 (low dose IV) | EXPERIMENTAL | Low dose administered by intraveneous (IV) infusion |
| Stage 2 (medium dose IV) | EXPERIMENTAL | Medium dose administered by intraveneous (IV) infusion |
| Stage 2 (high dose IV) | EXPERIMENTAL | High dose administered by intraveneous (IV) infusion |
| Placebo SC (Stage1) | PLACEBO_COMPARATOR | Placebo administered by subcutaneous (SC) injection |
| Placebo IV (Stage2) | PLACEBO_COMPARATOR | Placebo administered by intraveneous (IV) infusion |
| Name | Type | Description |
|---|---|---|
| ABBV-066 | DRUG | SC injection |
| Placebo | DRUG | SC injection (stage 1) |
Inclusion criteria: 1. Healthy male subjects according to the investigator¿s assessment, based on a complete medical history including a physical examination, vital signs (BP, PR), 12-lead ECG, and clinical laboratory tests 2. Chinese ethnicity, Japanese ethnicity, or Caucasian according to the fol...
ABBV-066 is an investigational small molecule being developed by AbbVie Inc. It is currently in Phase 1 clinical development. The drug has been studied in healthy volunteers, and it is not yet approved for any medical condition.
ABBV-066 is being studied for use in healthy volunteers, primarily to assess its safety, tolerability, and pharmacokinetics. It is not intended for treatment of any specific disease at this stage of development.
ABBV-066 is developed by AbbVie Inc., a biopharmaceutical company listed on the New York Stock Exchange under the ticker ABBV.
ABBV-066 is in Phase 1 clinical development. One Phase 1 trial has been completed, and the drug remains investigational, meaning it has not been approved by regulatory authorities.
ABBV-066 was studied in a completed Phase 1 trial with the identifier NCT02596217. This trial evaluated the safety, tolerability, and pharmacokinetics of the drug in healthy Asian and Caucasian male volunteers, enrolling 80 participants in Japan and South Korea.
Yes, ABBV-066 is also known as risankizumab and BI 655066. The completed Phase 1 trial NCT02596217 explicitly refers to the drug as BI 655066/ABBV-066 (Risankizumab).